Related Experiment Video

Updated: Jun 24, 2026

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering

Elias Fattal1, Gillian Barratt

  • 1Univ Paris Sud 11, UMR 8612, Châtenay-Malabry, F-92290, France.

British Journal of Pharmacology
|April 16, 2009
PubMed

Insights

Antisense oligonucleotides and small interfering RNA show promise for treating diseases like cancer. Polymer-based nano- and micro-delivery systems can overcome stability and cell penetration challenges for these therapeutic agents.

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Polymer Science

Background:

  • Antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) are potent therapeutic agents with potential applications in oncology.
  • Significant challenges hinder their clinical use, including poor stability in biological fluids and inefficient cellular uptake.

Purpose of the Study:

  • This review examines the progress in utilizing polymer-based drug delivery systems for ASOs and siRNA.
  • The focus is on overcoming the limitations of these nucleic acid-based therapies.

Main Methods:

  • The review synthesizes information on natural and synthetic polymer-based delivery systems.
  • Delivery strategies discussed include complexes, nanoparticles, and microparticles.

Main Results:

  • Polymer-based nano- and micro-delivery systems demonstrate potential in enhancing the stability and cellular delivery of ASOs and siRNA.
  • These systems offer a viable strategy to address key impediments for nucleic acid therapeutics.

Conclusions:

  • Drug delivery systems, particularly those utilizing polymers in nano- and micro-formulations, are crucial for the advancement of ASO and siRNA therapeutics.
  • Further development in this area holds promise for treating diseases, including cancer.

More Related Videos

Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers11:53

Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers

Published on: July 21, 2017

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...